
## **Dulce** Fontoura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6197862/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Current pathophysiological concepts and management of pulmonary hypertension. International Journal of Cardiology, 2012, 155, 350-361.	1.7	48
2	Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: an experimental study. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1556-H1563.	3.2	40
3	Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1648-H1654.	3.2	33
4	<i>In vitro</i> model to study the effects of matrix stiffening on Ca <sup>2+</sup> handling and myofilament function in isolated adult rat cardiomyocytes. Journal of Physiology, 2017, 595, 4597-4610.	2.9	28
5	Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H459-H475.	3.2	19
6	A Western-Type Diet Attenuates Pulmonary Hypertension with Heart Failure and Cardiac Cachexia in Rats. Journal of Nutrition, 2011, 141, 1954-1960.	2.9	17
7	Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e005596.	3.9	17
8	Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension. Revista Portuguesa De Cardiologia, 2014, 33, 213-222.	0.5	15
9	Spectral transfer function analysis of respiratory hemodynamic fluctuations predicts end-diastolic stiffness in preserved ejection fraction heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H4-H13.	3.2	12
10	Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 690-701.	2.0	9
11	Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension. Intensive Care Medicine, 2012, 38, 1050-1060.	8.2	8
12	Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome. Revista Espanola De Enfermedades Digestivas, 2017, 109, 491-497.	0.3	8
13	Myocardial and antiâ€inflammatory effects of chronic bosentan therapy in monocrotalineâ€induced pulmonary hypertension. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 213-222.	0.2	7